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Tumor Cell Responses to IFNg Affect Tumorigenicity
and Response to IL-12 Therapy and Antiangiogenesis
induce CD41 T helper cell differentiation along the TH1
pathway (Hsieh et al., 1993) and to enhance CD81 T cell
maturation and activation (Gately et al., 1992; Mehrotra
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CTLs and directs TH1 differentiation of naive CD41 T
cells. The IL-2 produced by TH1 cells favors CTL amplifi-Expression of a dominant negative mutant IFNgR1 in
cation, while the IFNg produced induces Ig class switch-murine SCK and K1735 tumor cells rendered them
ing by B cells toward production of opsonizing antibod-relatively unresponsive to IFNg in vitro and more tu-
ies. The response of nonimmune host cells also maymorigenic and less responsive to IL-12 therapy in vivo.
contribute to an antitumor effect. IL-12, through theIL-12 induced histologic evidence of ischemic damage
agency of IFNg, inhibits angiogenesis by mechanismsonly in IFNg-responsive tumors, and in vivo Matrigel
that are incompletely understood but involve IFNg in-vascularization assays revealed that while IFNg-respon-
duction of angiogenesis inhibitory chemokines, IP-10,sive and -unresponsive tumor cells induced angiogen-
and Mig (Voest et al., 1995; Streiter et al., 1995; Sgadariesis equally well, IL-12 and its downstream mediator
IFNg only inhibited angiogenesis induced by the re- et al., 1996, 1997). While IL-12 is known to act only on
sponsive cells. IL-12 induced angiogenesis inhibitory cells of the immune system, IFNg has effects on most
activity in the responsive cells, which may be attribut- somatic cells, including tumor cells. Through its ability
able to production of the chemokine IP-10. Thus, IL- to slow cell proliferation and up-regulate expression of
12 and IFNg inhibit tumor growth by inducing tumor MHC class I and the machinery of antigen presentation,
cells to generate antiangiogenic activity. IFNg can favor tumor regression by retarding tumor
growth and enhancing immunological recognition of tu-
Introduction mor cells and their antigens. Singly or in combination,
these effects of IL-12 and IFNg may be responsible for
Interleukin-12 (IL-12) is a cytokine with marked thera- their activity against tumors.
peutic effects against a wide variety of murine tumors We undertookthe current study toexamine how tumor
(Brunda et al., 1993; Nastala et al., 1994). Little is known cell responses to IFNg affect the antitumor activity of
about the mechanisms of IL-12 antitumor activity other IL-12. IFNg stimulates cells by binding to a receptor
than the lymphocyte subsets required and the impor- that is widely expressed on normal and malignant cells
tance of endogenous IFNg. Studies have shown that (Boehm et al., 1997). The functional IFNg receptor con-
CD41 and/or CD81 T cells are usually required for IL-12 sists of two components, IFNgR1 and R2, that dimerize
effectiveness (Brunda et al., 1993; Nastala et al., 1994). upon ligand binding. Receptor dimerization allows their
While the specific functions of these cells responsible transphosphorylation and activation of attached JAK1
for antitumor activity are unknown, IL-12 is known to and JAK2 tyrosine kinases (Kotenko et al., 1995, 1996)
and phosphorylation, dimerization, and nuclear translo-
cation of Stat1a (GAF, or gamma-interferon activated8 To whom correspondence should be addressed (e-mail: leemingf
@mail.med.upenn.edu). factor) (Pearse et al., 1993). Nuclear Stat1a binds gamma-
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themselves play an important role in the inhibition of
angiogenesis by IL-12.
Results
Impaired IFNg Responses in Tumor Cells Expressing
a Dominant Negative Mutant IFNgR1
Murine SCK mammary carcinoma cells and K1735 mela-
noma cells were transfected to express high levels of a
dominant negative mutant IFNgR1. Upon staining with
an antibody tomurine IFNgR1and flow cytometric analy-
sis, transfected clones SCK.F11 and SCK.F2 expressed
12- and 8-fold higher levels, respectively, of immunore-
active IFNgR1 than SCK cells, and clones K1735.N23
and K1735.N4 expressed 25- and 21-fold higher levels,
respectively, of immunoreactive IFNgR1 than K1735
cells. IFNg signaling was inhibited in these clones when
they were tested for IFNg induction of nuclear Stat1a.
Using EMSA and a radiolabeled GAS oligonucleotide
(Decker et al., 1997), rmIFNg treatment of SCK and
K1735 cells resulted in the appearance of a nuclear
complex that was efficiently inhibited by anti-Stat1a an-
tibody and by cold GAS oligonucleotide but not by anti-
Stat4 antibody or cold mutant GAS oligonucleotide (Fig-
ure 1A shows the results for SCK cells; not shown are
similar results for K1735 cells). If rmIFNg induction of
nuclearStat1a±GAS complex in SCKcells is100%, com-
plex induction in rmIFNg-stimulated SCK.F11 and SCK.F2
cells was 8% and 17%, respectively. If rmIFNg induction
of nuclear Stat1a±GAS complex in K1735 cells is 100%,
Figure 1. Stat1a Activation in SCK and K1735 Cells and Transfec- complex induction in rmIFNg-stimulated K1735.N23 and
tants Expressing a Dominant Negative Mutant IFNgR1
K1725.N4 cells was 2% and 11%, respectively (Figure
EMSA was performed with end-labeled GAS oligonucleotide and
1B).Downstream effects of IFNg signalingwere inhibitednuclear extracts from SCK, SCK.F11, and SCK.F2 cells and from
in SCK.F11 and F2 cells and in K1735.N23 and N4 cells.K1735, K1735.N23, and K1735.N4 cells. Nuclear extracts were pre-
By antibody staining and flow cytometry, H-2Dd expres-pared from IFNg-stimulated (for 15 min) or -unstimulated cells as
indicated. The band identified as Stat1a is indicated. sion increased 5.2-fold with rmIFNg treatment on SCK
(A) EMSA with SCK extract and labeled GAS probe competed with cells, increased 2.0-fold on treated SCK.F2 cells, and
either unlabeled GAS or mutant GAS oligonucleotides or treated did not increase at all on treated SCK.F11 cells. H-2Kk
with anti-Stat1 or anti-Stat4 antibodies.
expression increased 3.4-fold on K1735 cells exposed(B) Stat1a activation by IFNg was determined in SCK, SCK.F11, and
to rmIFNg but did not increase on treated K1735.N23SCK.F2 cells (left panel) and in K1735, K1735.N23, and K1735.N4
and K1735.N4 cells (data not shown). In vitro prolifera-cells (right panel).
tion rates in normal media of SCK, SCK.F11, and SCK.F2
cells and of K1735, K1735.N23, and K1735.N4 cells wereactivated sites (GAS) in IFNg-responsive genes to modu-
indistinguishable. Addition of rmIFNg inhibited theprolif-late transcription and bring about cellular changes asso-
eration of SCK cells by 43%, determined by [3H]thymi-ciated with IFNg (Darnell et al., 1994). Dighe et al. (1993,
dine uptake, but inhibited the proliferation of SCK.F21994) used a dominant negative mutant IFNgR1, trun-
and SCK.F11 cells by only 13% and 8%, respectively.cated in its cytoplasmic domain and missing both its
A similar reduction in IFNg-induced slowing of prolifera-JAK1 and Stat1a docking sites, to create Meth A sar-
tion was seen in K1735.N4 and K1735.N23 cells com-coma cells that were unresponsive to IFNg in order to
pared to K1735 cells. When control transfected SCK.nstudy theeffect of IFNg responses on tumorigenicity. We
and K1735.n cells expressing only the neor selectionadopted the same strategy to create IFNg-unresponsive
gene were compared to parental cells, no difference inSCK murine mammary carcinoma and K1735 murine
IFNg induction of MHC expression or slowing of cellmelanoma cells and found that the unresponsive cells
proliferation was noted. These results show that IFNgformed tumors more rapidly than the parental cells and
stimulation has little effect on SCK and K1735 cells ex-were relatively refractory to IL-12 treatment. Our studies
pressing our mutant IFNgR1 and that these cells areindicated that this behavior was not due to reduced
IFNg unresponsive to varying degrees.susceptibility to immunological rejection. Rather, IL-12,
via IFNg, effectively inhibited angiogenesis induced by
IFNg-Unresponsive Tumor Cells Are MoreIFNg-responsive but not by IFNg-unresponsive tumor
Tumorigenic and Less Sensitivecells, because only the former were induced by IFNg to
to IL-12 Therapyproduce angiogenesis inhibitory activity that may be
To examine the tumorigenicity of IFNg-unresponsive tu-attributable to the chemokine IP-10 (IFNg-inducible pro-
tein 10). These studies clearly indicate that tumor cells mor cells, cohorts of naive A/J mice were injected at
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To examine the effect of tumor cell IFNg unrespon-
siveness on IL-12 therapeutic efficacy, A/J mice inocu-
lated with SCK.F11, SCK.F2, or SCK.n cells were given
daily injections of rmIL-12 (0.25 mg/day 3 10 over 12
days). rmIL-12 treatment delayed SCK.n tumor appear-
ance by a median of 5 days but delayed SCK.F11 and
SCK.F2 tumor appearance by a median of 2 days (Figure
2). rmIL-12 treatment of C3H/HeN mice (0.125 mg/day 3
10 over 12 days) injected with K1735.n cells delayed
tumorigenesis by a median of 7 days but delayed tumori-
genesis by only 1 or 2 days in mice given K1735.N23 or
K1735.N4 cells, respectively (Figure 3). These results
indicate that IFNg-unresponsive tumor cells are less re-
sponsive to rmIL-12 therapy. In the SCK model, cells
engineered to express mIL-12 (SCK.12 cells) exert a
strong local antitumor effect that inhibits tumorigenesis
by colocalized SCK cells in 70% of mice (Coughlin et
al., 1998). We examined whether SCK cells have to be
IFNg responsive to respond to the local antitumor effect
of SCK.12 cells by injecting mice with an equal mixture
of SCK.12 cells and either SCK.n or SCK.F11 cells.
Whereas 3 of 10 mice given SCK.12/SCK.n cells devel-
oped tumors that appeared late, 4 of 5 mice given SCK.n/
SCK.F11 cells developed tumors that were delayed by
only a few days (Figure 4A). Systemically, SCK.12 cells
provide poor protection against SCK tumorigenesis
(only 10% of distant SCK tumors are prevented), which
is substantially improved when SCK cells engineered to
express mIL-18 (SCK.18 cells) are coinjected with the
SCK.12 cells (70% of distant SCK tumors are prevented
by SCK.12 1 SCK.18 cells). This protection depends on
IFNg and is abrogated by administration of neutralizing
anti-IFNg antibody (Coughlin et al., 1998). We examined
whether SCK cells have to be IFNg-responsive to be
Figure 2. Tumorigenesis by IFNg-Responsive and -Unresponsive
controlled by SCK.12 1 SCK.18 cells by injecting miceSCK Cells and Effects of rmIL-12 Therapy
with this mixture of cells in one flank and with SCK.n orCohorts of A/J mice were injected with 2.5 3 104 tumor cells on day
SCK.F11 cells in the opposite flank. Whereas 2 of 5 mice0, and rmIL-12 was administered on days 0±4 and 7±11 (0.25 mg/
receiving SCK.n cells developed tumors that appeareddose). Mice were monitored daily for tumor development. There
were five mice in each group. very late, all 5 mice receiving SCK.F11 cells rapidly de-
(A) Mice given control SCK.n or IFNg-unresponsive SCK.F11 cells. veloped fatal tumors that were delayed by only 2 days
(B) Mice given control SCK.n or IFNg-unresponsive SCK.F2 cells. (Figure 4B). These results indicate that tumor cells must
Black dashed lines, mice given IFNg-unresponsive cells; black solid
respond to IFNg to realize the benefits of secreted IL-lines, mice given IFNg-unresponsive cells 1 rmIL-12; gray dashed
12 or IL-12 1 IL-18 therapy.lines, mice given SCK.n cells; gray solid lines, mice given SCK.n
cells 1 rmIL-12.
IFNg-Unresponsive Tumor Cells Are Rejected
by Immune Micethe same time with 2.5 3 104 viable SCK.F11, SCK.F2,
or control SCK.n cells. SCK.F11 cells formed detectable A potential explanation for the refractoriness of IFNg-
unresponsive tumor cells to IL-12 therapy is that thesetumors after a median of 7 days, while SCK.F2 and
SCK.n cells formed tumors after a median of 10 days cells are less susceptible to immunological attack. To
explore this, we compared the ability of mice with antitu-(Figure 2). Injection of 106 K1735.N23 (Figure 3A) and
K1735.N4 (Figure 3B) cells into C3H/HeN mice produced mor immunity to reject IFNg-responsive and -unrespon-
sive tumor cells. A/J mice that had rejected a challengedetectable tumors after a median of 9 and 13 days,
respectively, which was faster than the median of 16 of SCK.B7±1 cells and a subsequent rechallenge of SCK
cells were injected a third time with either 1 3 105 SCK ordays it took for K1735.n cells to form tumors. A mouse
given K1735.n cells didnot develop a tumor in this exper- SCK.F11 cells. Two of 8 mice given SCK cells developed
tumors, whereas 1 of 8 mice given SCK.F11 cells devel-iment, which is not unusual inasmuch as 10% of mice
given 106 K1735 cells do not develop progressive tu- oped tumors. A/J mice that had survived SCK.B7±1 cells
with rmIL-12 treatment and that have a 90% probabilitymors. These results show that IFNg-unresponsive SCK
and K1735 cells form tumors more rapidly than their of having protective anti-SCK immunity (Coughlin et al.,
1995) were also tested. Two of 10 mice given SCK.F11IFNg-responsive counterparts. Once they appear, how-
ever, IFNg-responsive and unresponsive tumors enlarge cells and 1 of 10 mice given SCK cellsdeveloped tumors.
A similar experiment was performed in C3H/HeN miceat similar rates and kill the host (data not shown).
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Figure 3. Tumorigenesis by IFNg-Respon-
sive and -Unresponsive K1735 Cells and Ef-
fects of rmIL-12 Therapy
Cohorts of C3H/HeN mice were injected with
106 tumor cells on day 0, and rmIL-12 was
administered on days 0±4 and 7±11 (0.125 mg/
dose). Mice were monitored daily for tumor
development. There were five mice in each
group.
(A) Mice given control K1735.n or IFNg-unre-
sponsive K1735.N23 cells.
(B) Mice given control K1735.n or IFNg-unre-
sponsive K1735.N4 cells.
Black dashed lines, mice given IFNg-unre-
sponsive cells; black solid lines, mice given
IFNg-unresponsive cells 1 rmIL-12; gray
dashed lines, mice given K1735.n cells; gray
solid lines, mice given K1735.n cells 1
rmIL-12.
previously given K1735.B7±1 cells and rmIL-12. These and in other organs undergoing ischemic infarction and
suggests that ischemia is the major mechanism of cellmice never developed tumors (Coughlin et al., 1995) and
over 80% are immune to a rechallenge of K1735 cells death induced by rmIL-12 treatment in SCK.n tumors.
SCK.n, SCK.F11, and SCK.F2 tumors also had evidenceat day 30 (Townsend et al., 1994; unpublished data).
Rechallenge of these mice with either 106 K1735 or of individual tumor cell necrosis with nuclear fragmenta-
tion consistent with apoptosis (Figure 6B), suggestingK1735.N23 cells resulted in 3 of 20 developing K1735
tumors and 2 of 10 developing K1735.N23 tumors. These that mechanisms other than ischemia may also contrib-
ute to tumor cell death. However, the frequency of theseresults indicate that established antitumor immune re-
sponses do not require SCK or K1735 tumor cells to be apoptotic tumor cells did not vary signficantly among
the different tumors, did not correlate with rmIL-12 treat-IFNg responsive for rejection.
ment, and could not explain the resistance of IFNg-
unresponsive tumors to rmIL-12 treatment.Histology of IFNg-Unresponsive Tumors
We examined the histology of SCK.n, SCK.F2, and
SCK.F11 tumors to obtain clues for IFNg actions on Angiogenesis Induced by IFNg-Responsive
and -Unresponsive SCK Cellstumor cells that render them responsive to the antitumor
effects of IL-12. Untreated SCK.n tumors had small, The histology of the SCK tumors led us to assess their
ability to stimulate angiogenesis with in vivo Matrigelfocal areas of coagulative necrosis 4 days after they
became detectable (Figure 5A). Treatment of SCK.n tu- assays. Using hemoglobin content as an index of func-
tional Matrigel vascularization (Passaniti et al., 1992),mors with rmIL-12, however, led to broad areas of co-
agulative necrosis (Figure 5B). In contrast, untreated 105 SCK cells in the matrix induced vascularization
equivalent to 10 ng recombinant basic fibroblast growthSCK.F11 and SCK.F2 tumors had smaller areas of coag-
ulative necrosis than SCK.n tumors (Figures 5C and 5E), factor (rbFGF), and angiogenesis was inhibited by rmIL-
12 treatment of the host. IFNg neutralization abrogatedwhich did not increase with rmIL-12 treatment (Figures
5D and 5F). Coagulative necrosis in rmIL-12-treated rmIL-12 antiangiogenic activity showing that this activity
was mediated by IFNg (Figure 7A). To examine whetherSCK.n tumors (Figure 6A; higher magnification showing
hemorrhage and ghost outlines of tumor cells) resem- tumor cell responses to IFNg are important for rmIL-
12 inhibition of angiogenesis, Matrigel containing SCK,bles the pattern of necrosis seen in myocardial infarction
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factors following IFNg stimulation. IP-10, an IFNg-induc-
ible chemokine, has been identified as a mediator of IL-
12 antiangiogenic effect (Angiolillo et al., 1995). In vitro
treatment of SCK cells with rmIFNg at doses as low as
100 U/ml induced signficant IP-10 mRNA expression,
whereas treatment of SCK.F2 cells at 1000 and 10,000
U/ml induced much less IP-10 mRNA expression, and
treatment of SCK.F11 cells failed to induce detectable
expression (Figure 7C). Expression of another IFNg-
induced chemokine with antiangiogenic activity, Mig
(monokine induced by IFNg) (Sgadari et al., 1997), was
barely detectable in mRNA from rmIFNg-treated SCK
cells (data not shown). These results suggested that
IFNg-induced IP-10 production by SCK cells contributes
to rmIL-12 inhibition of SCK-induced angiogenesis, an
effect that is lost in SCK.F11 cells. The importance of
IP-10 as a mediator of angiogenesis inhibition was con-
firmed when administration of rabbit anti-mIP-10 serum,
but not normal rabbit serum, abrogated rmIL-12 inhibi-
tion of SCK-induced angiogenesis (Figure 7D).
Discussion
To examine the role of tumor cell responses to IFNg in
IL-12 antitumor responses, IFNg-unresponsive SCK and
K1735 tumor cells were created by expressing high lev-
els of a dominant negative mutant IFNgR1. These unre-
sponsive cells formed tumors more rapidly than control
cells and were relatively refractory to IL-12 therapy. To
investigate the effects of IFNg on tumor cells that con-
tribute to IL-12 antitumor efficacy, responsive and unre-
sponsive cells were tested in immune mice and found
to be equivalently rejected, indicating that the unrespon-
sive cells were susceptible to immunological rejection.
On the other hand,histology showed that tumors formed
Figure 4. Effect of Secreted IL-12 and IL-18 on Tumorigenesis by by unresponsive SCK cells displayed little evidence of
IFNg-Responsive and -Unresponsive SCK Cells
rmIL-12-induced ischemic necrosisseen in tumors formed
(A) Cohorts of A/J mice were injected with 2.5 3 104 SCK.n (gray by responsive SCK cells, and Matrigel assays indicated
dashed line) or SCK.F11 cells (black dashed line) or a mixture of
that rmIL-12 inhibited angiogenesis induced by the re-SCK.n 1 SCK.12 (2.5 3 104 cells of each type; gray solid line) or
sponsive but not by the unresponsive cells. Mixing ex-SCK.F11 1 SCK.12 cells (2.5 3 104 cells of each type; black solid
line) on day 0. periments showed that SCK responses to IFNg include
(B) Cohorts of A/J mice were injected with 2.5 3 104 SCK.n (gray the production of angiogenesis inhibitory activity, which
dashed lines) or SCK.F11 (black dashed lines) cells in the left flank. may be attributable to IFNg induction of IP-10 expres-
Some mice were also injected with a mixture of 2.5 3 104 SCK.12 1 sion. From this we conclude that direct actions of IFNg
2.5 3 104 SCK.18 cells in the right flank (solid lines). Mice were
on tumor cellscurb their tumorigenicity and that restraintmonitored daily for tumor development.
may be due, at least in part, to the inhibitory effects of
tumor cell IFNg responses on angiogenesis.
An earlier study by Dighe et al. (1994) of Meth A tumorSCK.F11, or SCK.F2 cells was implanted. The three cell
types induced equivalent vascularization (Figure 7B), cells rendered unresponsive to IFNg also found that
these cells were more tumorigenic, but the authors camebut while rmIL-12 inhibited vascularization induced by
SCK cells, it did not inhibit vascularization induced by to a different conclusion about mechanism. Immunologi-
cal studies indicated that these cells were less immuno-SCK.F11 or SCK.F2 cells. Thus, SCK responsiveness to
IFNg does not significantly affect basal angiogenesis genic and less susceptible to immune rejection than
control cells, and thus enhanced tumorigenicity was at-but is important for angiogenesis inhibition by rmIL-
12. To determine whether the IFNg-induced response tributed to an immunological mechanism. It is unclear
why IFNg-unresponsiveness affects immune recogni-in SCK cells involves reduced production of angiogenic
factors or increased production of angiogenesis inhibi- tion of Meth A versus SCK and K1735 cells differently,
but it may be due to tumor cell or model differences, e.g.,tors, a mix of 105 SCK and 105 SCK.F11 cells was placed
in Matrigel, and the recipient mice treated with rmIL-12. greater IFNg stimulation of Meth A's ability to present
antigen. However, whether reduced immune visibility ofAngiogenesis induced by the cell mixture was effectively
inhibited by rmIL-12 (Figure 7B), suggesting that SCK unresponsive Meth A cells causes accelerated tumori-
genesis is a separate question. The answer depends onbut not SCK.F11 cells produce angiogenesis inhibitory
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Figure 5. Histology of Tumors Produced by
IFNg-Responsive and -Unresponsive SCK
Cells
SCK.n, SCK.F11, and SCK.F2 tumors were
harvested from mice treated oruntreated with
rmIL-12 on the fourth day after the tumors
appeared, fixed in 10% buffered formalin,
sectioned, and stained with hematoxylin and
eosin. All sections are shown at 103 magnifi-
cation. (A and B) SCK.n tumors; (C and D)
SCK.F11 tumors; (E and F) SCK.F2 tumors.
(A), (C), and (E) are from untreated mice, and
(B), (D), and (F) are from rmIL-12-treated mice.
whether immune responses are elicited during tumori- duced by reactive host cells at low levels compared
to the large amount produced in response to rmIL-12genesis in naive mice and, if so, whether the response
retards tumor growth. Our finding that IFNg-responsive therapy, which probably explains why therapy widens
the interval between the appearance of IFNg-responsiveand -unresponsive SCK and K1735 cells are equally well
rejected by immune mice and thepoor intrinsic immuno- and -unresponsive tumors.
Mice given rmIL-12 produce high levels of IFNg, andgenicity of SCK cells suggest that any immunological
consequences of IFNg unresponsiveness are unlikely to IFNg effects should be more prominent. Therapy pro-
duces a marked slowing in the development of controlaccount for faster tumorigenesis by unresponsive SCK
and K1735 cells. SCK and K1735 tumors that is not seen with IFNg-unre-
sponsive SCK and K1735 tumors. This, together withIFNg-unresponsive tumor cells characteristically form
tumors faster than control cells in untreated miceÐa the observation that IFNg neutralization abrogates rmIL-
12 delay of tumorigenesis (Coughlin et al., 1995), allowsslight acceleration was seen with rapidly tumorigenic
SCK cells and marked acceleration was seen with more one to conclude that IFNg delays tumor development
and that its effects on tumor cells are at least partlyslowly tumorigenic K1735 cells. Since the behavior of
IFNg-responsive and -unresponsive cells should be in- responsible. Two well-known effects of IFNg on cells,
slowing of proliferation and enhancement of immuno-distinguishable in the absence of IFNg, and no in vitro
differences were observed without the addition of logical visibility, might explain the delay. We suspect,
however, that while IFNg slowing of tumor cell prolifera-rmIFNg, this suggests that IFNg is present in the in vivo
tumor cell environment and modifying the behavior of tion may contribute to delayed tumorigenesis, it does
not account for the delay. First, if cell proliferation ratesthe responsive tumor cells. IFNg is presumably pro-
Figure 6. Effect of rmIL-12 Treatment on the
Histology of SCK Tumors
Four day SCK.n tumors from mice treated
with rmIL-12 were harvested, fixed in 10%
buffered formalin, sectioned, and stained
with hemotoxylin and eosin.
(A) A 5003 magnification view showing an
area of coagulativenecrosis with hemorrhage
and residual ghost outlines of necrotic tumor
cells.
(B) A 5003 view showing nuclear fragments
of individual SCK tumor cells undergoing
apoptotic cell death (indicated by arrow-
heads) scattered in areas of live tumor cells.
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Figure 7. Angiogenesis Induced by IFNg-Responsive and -Unresponsive SCK Cells and the Effect of rmIL-12 Therapy
(A) Mice were injected subcutaneously with Matrigel alone or Matrigel containing 105 SCK cells. rmIL-12 was administered i.p. where indicated
(0.25 mg/dose) on days 0±4, and anti-IFNg was administered i.p. where indicated (0.5 mg/dose) on days 21, 1, and 3. Matrigel was harvested
on day 6, and angiogenesis was quantitated by determining the hemoglobin content of individual pellets.
(B) Matrigel assays were performed as described except that pellets contained 105 SCK, SCK.F11, or SCK.F2 cells or a mixture of 105 SCK.F11 1
105 SCK cells.
(C) Expression of mIP-10 mRNA determined by Northern analysis in SCK, SCK.F2, or SCK.F11 cells either unstimulated or stimulated with
various concentrations of rmIFNg in vitro for 48 hr. The blot was probed with either radiolabeled mIP-10 cDNA (upper panel) or ribosomal
protein L32 cDNA (lower panel).
(D) Matrigel assays were performed as described. Where indicated, rabbit anti-IP-10 serum or normal rabbit serum (NRS) (0.1 ml) was mixed
with 105 SCK cells in the Matrigel prior to implantation, and serum was given i.p. (0.3 ml/dose) where indicated on days 0, 2, and 4.
In (A), (B), and (D), each bar represents the mean hemoglobin content of three Matrigel implants with standard deviations indicated. Plus
signs and asterisks indicate groups with significantly different hemoglobin content (p , .05) by Student t test.
determine tumor growth rates, the growth of IFNg-unre- was proposed based on evidence of their reduced im-
munogenicity and enhanced ability to elude immunolog-sponsive tumors during IL-12 therapy should be faster
throughout their course, whereas only the early phase ical attack (Dighe et al., 1994). However, no such evi-
dence was found in the case of unresponsive SCK andof tumorigenesis (tumors ,1±2 mm in diameter) was
obviously accelerated. Additionally, we generated a K1735 tumors. Furthermore, such a mechanism would
only be reasonable in our models if antigen-specificclone of IFNg-unresponsive SCK cells that proliferates
noticeably more slowly in vitro than SCK or SCK.F11 immune responses retard the appearance of the paren-
tal tumor cells. SCKcells, especially, are poorly immuno-cells, yet forms detectable tumors with the rapidity of
SCK.F11 cells (unpublished data), indicating that the in genic (Coughlin et al., 1995), which makes the induction
of antigen-specific immunity improbable. Even if anti-vitro rate of tumor cell proliferation, in or out of the
presence of IFNg, does not predict or limit the speed of gen-specific immunity were induced, it would take time
to develop and be less likely to have its greatest effecttumor formation. An immunological explanation for the
faster appearance of IFNg-unresponsive Meth A tumors very early in tumorigenesis rather than later on, which
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is the opposite of what is observed. Most compelling, mechanisms involving macrophage and NK cells and
deviate and stimulate acquired immune responses (afterhowever, is the fact that administration of rmIL-12 at
the doses and on the schedule used here induces tran- a period of transient immune suppression by high-dose
rmIL-12 [Kurzawa et al., 1998]). Additionally, while thesient but profound suppression of immunological rejec-
tion mechanisms for SCK and K1735 tumors (Kurzawa model proposed can account for most of our observa-
tions, it does not explain all features of rmIL-12 angio-et al., 1998). For these reasons, we believe that IFNg
retards the appearance of SCK and K1735 tumors genesis inhibition. We and others (Voest et al., 1995)
have shown that rmIL-12 will inhibit Matrigel vasculariza-through mechanisms not involving antigen-specific im-
munity. tion induced by defined angiogenic factors such as
bFGF. This inhibition is dependent on endogenouslyTumor histology provided a critical clue to mecha-
nism when it revealednotably more coagulative necrosis produced IFNg and must be due to the effects of IFNg
(or its downstream mediators) on host cells. If IFNg'sin IFNg-responsive than in IFNg-unresponsive tumors
treated with rmIL-12. This type of injury often results effects on host cells can prevent Matrigel vasculariza-
tion stimulated by bFGF, why are these effects insuffi-from ischemic damage and suggests that responsive
tumors may experience vascular insufficiency that the cient to prevent vascularization stimulated by SCK.F2
or SCK.F11 cells? We do not have answers at this time,unresponsive tumors do not. Given that rmIL-12 inhi-
bition of angiogenesis is dependent on IFNg, these ob- but we can speculate without proof that the angiogenic
factors produced by SCK cells are different or moreservations suggested a difference in susceptibility of
IFNg-responsive and -unresponsive tumors to IFNg's complex than bFGF and that the angiogenic mecha-
nisms they stimulate are inadequately inhibited by theantiangiogenic effects, which was experimentally con-
firmed when rmIL-12 was found to inhibit angiogenesis actions of IFNg acting on host cells. Additional studies
will be required to address this issue and others aboutstimulated by SCK cells but not by SCK.F11 or SCK.F2
cells. This difference reasonably accounts for the ob- the angiogenesis inhibitor(s) and inducers produced by
the tumor cells.served difference in tumorigenic behavior between IFNg-
responsive and -unresponsive cells, because angiogen-
Experimental Proceduresesis is needed for tumor growth beyond small nests and
is often growth limiting. We hypothesize that the limited
Mice and Cell Linesamount of IFNg around the tumor cell inoculum in un-
Female A/J mice, 6±8 weeks old, were purchased from the Jackson
treated mice retards angiogenesis modestly while the Laboratory (Bar Harbor, ME). Female C3H/HeN mice of a similar age
greater amount of IFNg induced by rmIL-12 treatment were purchased from Harlan Sprague Dawley (Indianapolis, IN). All
retards angiogenesis markedly, producing significant animals were maintained in microisolator cages and handled under
aseptic conditions. The SCK mammary carcinoma cell line (Song etdelays in tumor development. When the cells are IFNg
al., 1994) is maintained in RPMI medium supplemented with 10%unresponsive, neither spontaneously produced nor rmIL-
FCS and penicillin/streptomicin. The K1735 melanoma cell line12-stimulated IFNg retards angiogenesis, and tumor
(Kripke, 1979) is maintained in DMEM supplemented with 10% FCS
growth in rmIL-12-treated and -untreated mice contin- and penicillin/streptomicin. In vitro culture with rmIFNg was done
ues unabated. That rmIL-12 inhibits angiogenesis stimu- in the respective media and for the times and doses indicated in
lated by a mix of responsive and unresponsive SCK the figure legends.
For MHC induction studies, SCK and K1735 cells were stimulatedcells but not by unresponsive cells alone suggests that
with 10,000 U/ml rmIFNg for 48 hr prior to staining for flow cytometry.refractoriness to rmIL-12 inhibition is due to failure of
For proliferation studies, cells (104/well) in 96-well plates wereIFNg-unresponsive SCK cells to produce angiogenesis
treated or untreated with 10,000 U/ml rmIFNg for 24 hr after which
inhibitors in response to IFNg. We believe the chemokine they were pulsed with 1 mCi [3H]thymidine/well for 16 hr. Cells were
IP-10 may be the SCK cell±produced mediator of rmIL- harvested with a Cambridge Technology PHD Harvester (Cam-
12/IFNg angiogenesis inhibition. This is based on its bridge, MA), and incorporated radioactivity was measured in tripli-
cate cultures by scintillation counting. Percent suppression of prolif-known antiangiogenic properties (Angiolillo et al., 1995;
eration by IFNg 5 [1 2 (cpm1IFNg/cpm2IFNg)] 3 100%.Sgadari et al., 1996); the fact that it is induced markedly
in SCK cells, weakly in SCK.F2 cells, and not at all in
Vectors and Cell TransfectionsSCK.F11 cells; and the fact that its neutralization by anti-
The plasmid pEF2.mugR is an expression plasmid that contains
body abrogates rmIL-12 inhibition of SCK-induced angi- a truncated murine IFNgR1 cDNA under control of the eukaryotic
ogenesisis. However, a role for other IFNg effects on translation elongation factor 1a promoter (Goldman et al., 1996).
SCK cells during rmIL-12 angiogenesis inhibition (e.g., The truncated receptor cDNA clone was created by amplifying the
mIFNgR1 cDNA from nucleotides 106 to 949 (Gray et al., 1989).potential production of other angiogenesis inhibitors or
This expression contruct codes for the IFNgR1 signal sequence,reduced synthesis of angiogenesis stimulants) cannot be
extracellular and transmembrane domains, and only four aminoexcluded without additional studies.
acids of the intracellular domain (Gray et al., 1989). The truncated
The model we are proposing implies that IL-12 is pri- IFNgR1 cDNA was cloned into the BamHI and EcoRI sites of the
marily effective against certain murine tumors due to pEF2 expression vector, which contains a neor gene. To create SCK
inhibition of tumor angiogenesis and that tumor cell re- and K1735 cells expressing this mutant IFNgR1, parental cell lines
were transfected with pEF2.mugR by the calcium phosphatesponses to treatment are important for this inhibition. It
method. Individual G418-resistant clones were screened by flowdoes not imply that other antitumor mechanisms are not
cytometry (described below) to identify those with the highest sur-involved. IFNg has direct effects on tumor cells that may
face expression of the IFNgR complex. Control SCK.n cells are a
restrain tumorigenesis, e.g., enhanced susceptibility to pool of cells created by transfecting SCK cells with the empty pEF2
killing or apoptosis and slowed proliferation, which may vector and selecting with G418; K1735.n cells are a pool created
limit tumor growth when blood supply is abundant. IL-12 by transfecting K1735 cells with another neor empty vector, pMV6,
and selecting with G418. SCK cells expressing IL-12 or IL-18 wereand IFNg may effectively stimulate host innate immune
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created previously (Coughlin et al., 1998). Briefly, SCK.12 cells were Hybridizations were carried out by modifications of the methods of
Church and Gilbert (1984) using probes labeled by random priming.created by transfecting SCK cells with an expression plasmid,
pWRG, containing both the p35 nd p40 cDNAs under control of the mIP-10 was amplified from splenic RNA from a C57BL6 mouse
treated with BCG and LPS using published primers (Luster andCMV promoter (Tan et al., 1996). Cells were plated by limiting dilution
and screened by p70 radioimmunoassay. To create SCK.18 cells, Leder, 1993).
the retroviral expression construct pL(IL-18)SN was transfected into
ccre cells to create L(IL-18)SN retrovirus (Miller and Rosman, 1989), Purification of Nuclear Extracts
which was used to infect SCK cells. Individual G418-resistant clones Cells grown in a monolayer were treated (or untreated) with rmIFNg
were screened by Northern analysis and IL-18 ELISA. for 15 min and were lysed in hypotonic buffer (10 mM HEPES [pH
7.9], 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) and centrifuged at
Flow Cytometry 3500 rpm for 5 min to isolate nuclei. Nuclei were lysed in 0.53
To determine surface expression of murine IFNgR complexes, SCK volume low-salt buffer (20 mM HEPES [pH 7.9], 1.55 mM MgCl2, 20
or K1735 cells were stained with primary monoclonal rat anti-IFNgR1 mM KCl, 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT) and an equal
antibody (clone GR.20, PharMingen, Inc.) or rat isotype (IgG2a) and volume of high-salt buffer (20 mM HEPES [pH 7.9], 1.5 mM MgCl2,
secondary goat anti-rat IgG Fluorescein (FITC) conjugated antibody 1.2 M KCl, 25% glycerol, 0.2 nM EDTA, 0.5 mM DTT). Protein from
[F(ab9)2 fragment specific, Jackson Immunoresearch Laboratories, lysed nuclei was harvested by rotation at 48C for 30 min and centrifu-
Inc.]. To determine surface expression of murine MHC class I mole- gation at 15,000 rpm for 30 min. Protein extracts were quantitated
cules, SCK cells were stained with primary monoclonal mouse anti- using the MicroBCA protein assay kit (Pierce).
H-2Dd antibody (clone 34±5±8S, PharMingen, Inc.), and K1735 cells
were stained with monoclonal mouse anti-H-2Kk antibody (clone Gel Electrophoretic Mobility Shift Assay (EMSA)
36±7±5, PharMingen, Inc.) and secondary goat anti-rat IgG fluores- End-labeled duplexed oligonucleotide GAS probes (Decker et al.,
cein (FITC)-conjugated antibody [F(ab9)2 fragment specific, Jackson 1997) (50,000 cpm/sample) were mixed with 12 mg crude nuclear
Immunoresearch Laboratories, Inc.]. Fluorescence was determined extracts and incubated at room temperature for 20±30 min in the
on a FACScan flow cytometer using CELLQuest software (Becton presence of 1 mg poly(dI-dC) in a volume of 10 ml containing 1 ml
Dickinson). Mean fluorescence intensity (MFI) was determined by 103 binding buffer (100 mM HEPES [pH 7.9], 80 mM KCl, 50%
dividing the geometric means of the specific antibody by that of the glycerol, 0.25 dithiothreitol, 0.25 mM phenylmethylsufonyl fluoride,
isotype antibody (MFI 5 geometric mean (anti-IFNgR)/geometric 10 mg/ml leupeptin, 10 mg/ml pepstatin, 10 mg/ml aprotinin). The
mean (isotype)). Induction 5 MFI1IFNg/MFI2IFNg. mix was then fractionated through a 4% acrylamide gel in buffer
containing 100 mM Tris base, (pH 7.5), 0.3 M sodium acetate, 50
Tumorigenicity Studies mM EDTA for 1 hr at 200 V. The gel was dried and exposed to a
Tumorigenesis studies using SCK cells were carried out by injecting PhosphorImager storage screen (Molecular Dynamics), scanned,
2.5 3 104 trypan blue±excluding cells (typically, 80%±90% of all cells) and quantitated. Antibody competition experiments were carried
subcutaneously in the right flank of each A/J mouse. Tumorigenesis out by preincubating the nuclear extract with monoclonal anti-Stat1
studies using K1735 cells were carried out similarly except that 1 3 (anti-Stat91, clone C-111, Santa Cruz) or anti-Stat4 (clone L-18,
106 trypan blue±excluding cells were injected into each C3H/HeN Santa Cruz) antibody for 30 min at 48C before the probe was added.
mouse. The cells injected were obtained from cultures established Probe competition experiments were carried out using either unla-
from low-passage, frozen stocks less than 1 week prior to injection. beled GAS probe (59 AGC-TTG-TAT-TTC-CCA-GAA-AAG-GGA-TC)
rmIL-12 was administered on a 10 dose/12 day schedule (days 0±4 or a labeled probe that contains a mutated GAS-binding site (59
and 7±11 with tumor cells injected on day 0). The dose of rmIL-12 AGC-TTG-TAT-GGA-TTG-TCC-AAG-GGA-TC) (Decker et al., 1997).
was 0.25 mg/day for A/J mice and 0.125 mg/day for C3H/HeN mice, Sp1 binding was determined by the same binding reactions using
their respective maximum tolerated dose. Mice weremonitored daily an Sp1 oligonucleotide probe. Specific Stat1a binding for a specific
for development and growth of tumors and were euthanized ac- sample was determined by (binding activity of Stat1a)/(binding ac-
cording to guidelines established by the Institutional Animal Care tivity of Sp1). Activation of wild-type cells was normalized to 100%
and Use Committee. binding. IFNg activation of Stat1a binding activity in wild-type and
IFNg-unresponsive clones was determined by the following equa-
Matrigel Assay for Angiogenesis tion: Stat1a activity (1 IFNg) 5 [(Stat1aIFNg activity)/(Sp1IFNg activity)]/
Angiogenesis assays werecarried out by injecting A/J mice subcuta- [(Stat1ano IFNg activity)/(Sp1no IFNg activity)].
neously with 0.5 ml Matrigel (Collaborative Biomedical Products;
Kleinman et al., 1982) mixed with 1 3 105 SCK, SCK.F11, or SCK.F2 Acknowledgments
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